Keuangan Cigna (CI)
NYSE · Healthcare · Medical - Healthcare Plans · Karyawan: 66.685 · CEO: Brian C. Evanko
- Harga
- $298,23 -0,06%
- Kapitalisasi pasar
- $78,8 M
- Nilai perusahaan
- $104 M
- Laporan terakhir
- Q2 '26 diajukan 2026-07-30
- Laporan berikutnya
- 2026-11-05 Estimasi EPS: $7,52
Pendapatan (TTM)$282 M+7,7% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)3,5%0,0 poin vs tahun laluLaba operasional: $9,76 M
Laba bersih (TTM)$6,42 M+27,9% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$9,11 M+131,1% vs tahun laluCapex: $1,16 M
EPS dilusian (TTM)$24,16+31,9% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$25,6 M+0,2% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $78,8 M EV $104 M
- Pendapatan
- $282 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +5% Konsensus FY2026
- Margin laba
- 2,3% Laba bersih / pendapatan, TTM
- P/E
- 12,3× Forward 9,8× (FY2026)
- P/S
- 0,3× Harga / penjualan, TTM
- EV / EBITDA
- 8,3× TTM
- Arus kas bebas
- $9,11 M 12 bulan terakhir
- Laba bersih
- $6,42 M 12 bulan terakhir
- Estimasi pendapatan
- $287 M Konsensus FY2026
- Laba
- 2026-11-05 Estimasi pendapatan: $72,6 M
- Dividen
- $6,19 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-07-30): pendapatan melampaui 2,2%, EPS melampaui 2,4%Pendapatan $71,7 M vs $70,1 M yang diharapkan (+2,2%); EPS $7,78 vs $7,60 (+2,4%).
- Pertumbuhan pendapatan melambat: 6,6% yoyPendapatan Q2 '26: $71,7 M, rata-rata empat kuartal sebelumnya: 8,9%.
- Margin operasional 3,5% (TTM), dibanding tahun lalu: 0,0 poinLaba operasional tumbuh 6,6%, pendapatan tumbuh 7,7%.
- 15,5% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $8,45 M vs laba operasional $9,76 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 0,4% dari pendapatan (tahun lalu 0,5%)$1,16 M diinvestasikan dalam 4 kuartal terakhir (-13,6% dibanding tahun sebelumnya). Arus kas bebas: $9,11 M = 142,0% dari laba bersih.
- $2,91 M dikembalikan ke pemegang saham = 31,9% dari arus kas bebasBuyback: $1,28 M (tahun lalu $4,64 M), dividen: $1,62 M, kompensasi saham: $0 (TTM).
- Jumlah saham dilusian turun dalam setahun: 1,6%Saham dilusian pada Q2 '26: 264 jt, setahun sebelumnya: 268 jt.
- Utang neto: $25,6 MKas + investasi jangka pendek: $6,3 M, utang termasuk sewa: $31,9 M; tahun lalu utang neto: $25,6 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $71,7 M | $67,2 M | +6,6% |
| Margin kotor | 20,9% | 11,7% | +9,2 poin |
| Laba operasional | $2,68 M | $2,43 M | +10,0% |
| Margin operasional | 3,7% | 3,6% | +0,1 poin |
| Laba bersih | $1,66 M | $1,53 M | +8,4% |
| EPS dilusian | $6,29 | $5,71 | +10,2% |
| Arus kas operasional | -$421 jt | -$1,89 M | +77,7% |
| Capex | $297 jt | $285 jt | +4,2% |
| Arus kas bebas | -$718 jt | -$2,17 M | +66,9% |
| R&D | $0 | $0 | – |
| Kompensasi berbasis saham | $0 | $0 | – |
Dilaporkan vs konsensus
2026-07-30| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $71,7 M | $70,1 M | +2,2% |
| EPS (basis konsensus) | $7,78 | $7,60 | +2,4% |
Dari laporan 2026-07-30 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Evernorth | $61,5 M | +6,3% | 83,9% | $245 M | -5,2% | |
| Cigna Healthcare | $11,8 M | +9,6% | 16,1% | $46,8 M | -19,8% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $10,3 M
- Capex
- -$1,16 M
- Buyback
- -$1,28 M
- Dividen
- -$1,62 M
- Akuisisi
- $1,78 M
- Utang neto diterbitkan
- $1,06 M
- Kompensasi berbasis saham
- $0
- Arus kas bebas
- $9,11 M
- Dikembalikan ke pemegang saham / FCF
- 31,9%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 12,3× | 16,3× | 12,3× – 22,5× |
| EV / EBITDA | 8,3× | 9,3× | 8,2× – 11,2× |
| EV / Penjualan | 0,4× | 0,5× | 0,4× – 0,7× |
| Harga / FCF | 8,6× | 10,6× | 8,6× – 14,1× |
| Harga / Nilai buku | 1,8× | 1,9× | 1,6× – 2,3× |
| Imbal hasil FCF | 11,6% | 9,9% | 7,1% – 11,6% |
| Imbal hasil modal yang diinvestasikan | 7,7% | 6,8% | 5,6% – 7,8% |
| Imbal hasil ekuitas | 15,2% | 12,0% | 8,4% – 14,9% |
Analis
Target konsensus $342,08 (+14,7%)
rentang $302,00 – $400,00 · peringkat Buy
Beli kuat0
Beli29
Tahan10
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $287 M | +4,5% | $30,51 | +37,6% | 9,8× | 15 |
| FY2027 | $300 M | +4,3% | $33,49 | +9,8% | 8,9× | 15 |
| FY2028 | $316 M | +5,4% | $37,14 | +10,9% | 8,0× | 12 |
| FY2029 | $336 M | +6,2% | $41,33 | +11,3% | 7,2× | 9 |
| FY2030 | $348 M | +3,6% | $46,63 | +12,8% | 6,4× | 5 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 263 angka yang ditandai Cigna Corporation dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts and Other Receivables, Net, Current | $218 jt | $758 jt | -71,2% | $239 jt | – | – |
| Accounts Payable, Current | $10,4 M | $9,94 M | +4,7% | $10,7 M | $9,29 M | +14,7% |
| Accounts Receivable, Allowance for Credit Loss, Current | $195 jt | $388 jt | -49,7% | $199 jt | $84 jt | +136,9% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $10,1 M2025-12-31 | – | – | $10,1 M | – | – |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$4,36 M | -$2,82 M | -54,9% | -$2,81 M | -$2,34 M | -19,9% |
| Additional Paid in Capital, Common Stock | $32,1 M | $31,6 M | +1,6% | $31,8 M | $31,3 M | +1,6% |
| Additions to Contract Holders Funds | $35 jt | $38 jt | -7,9% | $152 jt | $166 jt | -8,4% |
| Amortization of Intangible Assets | $389 jt | $422 jt | -7,8% | $1,74 M | $1,7 M | +2,3% |
| Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries | $11,3 M2025-12-31 | $11,3 M | 0,0% | $11,3 M | $11,3 M | 0,0% |
| AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax | $34 jt | $56 jt | -39,3% | $40 jt | $53 jt | -24,5% |
| Assets | $157 M | $152 M | +3,6% | $158 M | $156 M | +1,3% |
| Assets Held by Insurance Regulators | $300 jt2025-12-31 | $400 jt | -25,0% | $300 jt | $400 jt | -25,0% |
| Assets, Current | $47 M | $44,7 M | +5,1% | $47,8 M | $48,9 M | -2,2% |
| Benefits, Losses and Expenses | $69 M | $64,9 M | +6,4% | $266 M | $238 M | +11,8% |
| Cash and Cash Equivalents, at Carrying Value | $6,3 M | $4,33 M | +45,5% | $7,68 M | $7,55 M | +1,7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $6,36 M | $4,39 M | +44,9% | $7,74 M | $7,59 M | +1,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations | $02025-12-31 | $1,34 M | -100,0% | $0 | $1,34 M | -100,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $7,74 M2025-12-31 | $8,93 M | -13,4% | $7,74 M | $8,93 M | -13,4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$724 jt | -$3,99 M | +81,9% | -$1,2 M | $594 jt | -301,2% |
| Commercial Paper | $1 M | – | – | $0 | $880 jt | -100,0% |
| CommercialPaperAverageRatePaid | – | – | – | 4,7%2024-12-31 | 5,6% | -17,4% |
| Common Stock, Dividends, Per Share, Declared | $1,56 | $1,51 | +3,3% | $6,04 | $5,60 | +7,9% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 600 jt | 600 jt | 0,0% | 600 jt | 600 jt | 0,0% |
| Common Stock, Shares, Issued | 406 jt | 404 jt | +0,5% | 405 jt | 403 jt | +0,5% |
| Common Stock, Shares, Outstanding | 263 jt2025-12-31 | 274 jt | -3,8% | 263 jt | 274 jt | -3,8% |
| Common Stock, Value, Issued | $4 jt | $4 jt | 0,0% | $4 jt | $4 jt | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | – | – | – | $331 jt | $344 jt | -3,8% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $897 jt | $1,31 M | -31,3% | $5,49 M | $2,96 M | +85,7% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $1,11 M | $1,41 M | -20,9% | $5,82 M | $3,3 M | +76,4% |
| Cost of Goods and Services Sold | $56,7 M | $53,3 M | +6,4% | $215 M | $183 M | +17,8% |
| Current Federal Tax Expense (Benefit) | – | – | – | $807 jt | $1,17 M | -30,8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $191 jt | $248 jt | -23,0% |
| Current Income Tax Expense (Benefit) | – | – | – | $1,17 M | $1,59 M | -26,4% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $169 jt | $171 jt | -1,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $159 jt | $172 jt | -7,6% | $206 jt | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $401 jt | $456 jt | -12,1% | $367 jt | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | $1,87 M | $2,03 M | -7,9% | $1,97 M | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $2,03 M | $2,28 M | -10,8% | $2,03 M | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $3,99 M | $3,59 M | +11,3% | $3,7 M | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $600 jt | $620 jt | -3,2% | $695 jt | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $1,71 M | $1,84 M | -7,1% | $1,82 M | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $2,01 M | $2,2 M | -9,0% | $2 M | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $3,94 M | $3,56 M | +10,7% | $3,7 M | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $574 jt | $543 jt | +5,7% | $598 jt | – | – |
| Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Amortized Cost | $247 jt | $277 jt | -10,8% | $267 jt | – | – |
| Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value | $227 jt | $249 jt | -8,8% | $244 jt | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $4,86 M | $4,25 M | +14,3% | $3,73 M | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $401 jt | $456 jt | -12,1% | $367 jt | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | 1.882 position | 1.560 position | +20,6% | 1.273 position | – | – |
| Debt, Current | $2,79 M | $4,29 M | -34,9% | $592 jt | $3,04 M | -80,5% |
| DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest | $51 jt | $124 jt | -58,9% | $137 jt | – | – |
| DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss | $8,74 M | $8,8 M | -0,6% | $8,66 M | – | – |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterest | $8,45 M | $8,39 M | +0,7% | $8,36 M | – | – |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$69 jt | -$142 jt | +51,4% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $447 jt | $64 jt | +598,4% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $326 jt | -$95 jt | +443,2% |
| Deferred Income Tax Liabilities, Net | $6,73 M | $6,78 M | -0,7% | $7,15 M | $6,98 M | +2,4% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$52 jt | -$17 jt | -205,9% |
| Deferred Tax Assets, Capital Loss Carryforwards | $237 jt2025-12-31 | $773 jt | -69,3% | $237 jt | $773 jt | -69,3% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01